<p>Beta Bionics（纳斯达克股票代码：BBNX - 获取免费报告）在周一发布的研究报告中，Truist Financial 的股票研究分析师将其目标价格从 37.00 美元下调至 25.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。Truist Financial 的价格目标表明，从公司当前价格来看，潜在上涨幅度为 80.12%。</p>
<p>其他一些股票研究分析师最近也对该公司发表了看法。Robert W. Baird 在 12 月 16 日的报告中对 Beta Bionics 设定了 28.00 美元的价格目标。Lake Street Capital 在 1 月 9 日的研究报告中将 Beta Bionics 的目标价格从 35.00 美元上调至 40.00 美元，并给予该公司 “买入” 评级。Piper Sandler 在 10 月 29 日的报告中重申了 “增持” 评级，并将 Beta Bionics 的价格目标设定为 32.00 美元（之前为 26.00 美元）。Stifel Nicolaus 在 10 月 29 日的研究报告中重新发布了 “买入” 评级，并将 Beta Bionics 的价格目标设定为 31.00 美元（之前为 26.00 美元）。最后，美国银行在 1 月 9 日的报告中将 Beta Bionics 的评级从 “买入” 下调至 “中性”。一位分析师给予该股票 “强烈买入” 评级，六位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均价格目标为 27.18 美元。</p>
<p><strong>阅读我们关于 BBNX 的最新报告</strong></p>
<h2>Beta Bionics 股票上涨 0.4%</h2>
<p>在周一的交易中，纳斯达克：BBNX 的股票上涨了 0.05 美元，达到 13.88 美元。该公司共有 70,781 股股票交易，较其平均交易量 1,462,587 股有所减少。该公司的市值为 6.1114 亿美元，市盈率为-3.18。Beta Bionics 的 52 周低点为 8.89 美元，52 周高点为 32.71 美元。该公司的 50 日简单移动平均线为 25.98 美元，200 日简单移动平均线为 22.68 美元。</p>
<h2>内部交易活动</h2>
<p>在相关消息中，首席财务官 Stephen Feider 在 1 月 2 日的交易中出售了 20,000 股 Beta Bionics 的股票。这些股票的平均售价为 29.53 美元，总交易额为 590,600.00 美元。交易完成后，首席财务官持有公司 42,614 股股票，价值 1,258,391.42 美元。这笔交易代表了他们持股比例的 31.94% 的减少。该出售在向证券交易委员会的备案中披露，相关信息可在 SEC 网站上找到。此外，内部人士 Mike Mensinger 在 1 月 2 日的交易中出售了 7,800 股公司的股票。这些股票的平均售价为 29.61 美元，总价值为 230,958.00 美元。交易完成后，该内部人士直接持有公司 82,952 股股票，价值 2,456,208.72 美元。这笔交易代表了他们持股比例的 8.59% 的减少。该出售的 SEC 备案提供了更多信息。在过去三个月中，内部人士共出售了价值 960,835 美元的 32,490 股公司股票。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。先锋集团（Vanguard Group Inc.）在第三季度将其在 Beta Bionics 的持股比例提高了 213.5%。先锋集团目前拥有 2,216,185 股公司股票，价值 44,036,000 美元，在上个季度又购买了 1,509,217 股。Divisadero Street Capital Management LP 在第二季度获得了 Beta Bionics 的新股份，价值约为 13,817,000 美元。Sands Capital Alternatives LLC 在第二季度将其在 Beta Bionics 的持股比例提高了 15.0%。Sands Capital Alternatives LLC 目前拥有 3,570,113 股公司股票，价值 51,981,000 美元，在上个季度又购买了 466,331 股。Soleus Capital Management L.P.在第二季度将其在 Beta Bionics 的持股比例提高了 12.5%。Soleus Capital Management L.P.目前拥有 3,820,158 股公司股票，价值 55,622,000 美元，在此期间又购买了 424,817 股。最后，Pura Vida Investments LLC 在第三季度将其在 Beta Bionics 的持股比例提高了 11,150.0%。Pura Vida Investments LLC 目前拥有 281,250 股公司股票，价值 5,588,000 美元，在上个季度又购买了 278,750 股。</p>
<h2>Beta Bionics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Beta Bionics 是一家总部位于马萨诸塞州波士顿的临床阶段医疗设备公司，专注于通过自动胰岛素输送解决方案来彻底改变 1 型糖尿病的管理。该公司的旗舰产品 iLet Bionic Pancreas 系统旨在通过自动调整胰岛素剂量以响应连续血糖监测数据，从而简化血糖控制。通过将先进的算法控制与可穿戴输注泵相结合，iLet 旨在减少糖尿病管理的日常负担，并改善患者的临床结果。</p>
<p>Beta Bionics 产品的核心是其专有的仿生胰腺软件，该软件可以在仅胰岛素和双激素模式下运行。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 Beta Bionics 更好</li>
<li>特朗普刚刚签署了</li>
<li>这是人工智能繁荣结束的确切时刻</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkJOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkJOWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Beta Bionics 吗？</h2>
<p>在考虑 Beta Bionics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Beta Bionics 并不在名单上。</p>
<p>虽然 Beta Bionics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BBNX

<p>Truist Financial 将 Beta Bionics (NASDAQ:BBNX) 的目标股价从 37.00 美元下调至 25.00 美元，同时维持 “买入” 评级。这一调整表明，从当前价格 13.88 美元来看，潜在上涨幅度为 80.12%。其他分析师的看法各异，目标股价范围在 28.00 美元至 40.00 美元之间。该股票的共识评级为 “适度买入”，平均目标股价为 27.18 美元。最近的内部交易显示，首席财务官 Stephen Feider 和另一位内部人士进行了大量股票出售，表明他们的持股比例有所下降</p>

<p>Beta Bionics (NASDAQ:BBNX - Get Free Report) had its price target cut by equities research analysts at Truist Financial from $37.00 to $25.00 in a research note issued on Monday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Truist Financial's price objective indicates a potential upside of 80.12% from the company's current price.</p>
<div class="lb-trans"><p>Beta Bionics（纳斯达克股票代码：BBNX - 获取免费报告）在周一发布的研究报告中，Truist Financial 的股票研究分析师将其目标价格从 37.00 美元下调至 25.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。Truist Financial 的价格目标表明，从公司当前价格来看，潜在上涨幅度为 80.12%。</p>
</div><p>A number of other equities research analysts also recently weighed in on the company. Robert W. Baird set a $28.00 price objective on Beta Bionics in a report on Tuesday, December 16th. Lake Street Capital boosted their target price on shares of Beta Bionics from $35.00 to $40.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, January 9th. Piper Sandler reiterated an &#34;overweight&#34; rating and issued a $32.00 price objective (up previously from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Stifel Nicolaus reissued a &#34;buy&#34; rating and issued a $31.00 price objective (up from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. Finally, Bank of America downgraded Beta Bionics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $27.18.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对该公司发表了看法。Robert W. Baird 在 12 月 16 日的报告中对 Beta Bionics 设定了 28.00 美元的价格目标。Lake Street Capital 在 1 月 9 日的研究报告中将 Beta Bionics 的目标价格从 35.00 美元上调至 40.00 美元，并给予该公司 “买入” 评级。Piper Sandler 在 10 月 29 日的报告中重申了 “增持” 评级，并将 Beta Bionics 的价格目标设定为 32.00 美元（之前为 26.00 美元）。Stifel Nicolaus 在 10 月 29 日的研究报告中重新发布了 “买入” 评级，并将 Beta Bionics 的价格目标设定为 31.00 美元（之前为 26.00 美元）。最后，美国银行在 1 月 9 日的报告中将 Beta Bionics 的评级从 “买入” 下调至 “中性”。一位分析师给予该股票 “强烈买入” 评级，六位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均价格目标为 27.18 美元。</p>
</div><p><strong>Read Our Latest Report on BBNX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 BBNX 的最新报告</strong></p>
</div><h2>Beta Bionics Stock Up 0.4%</h2>
<div class="lb-trans"><h2>Beta Bionics 股票上涨 0.4%</h2>
</div><p>Shares of NASDAQ:BBNX traded up $0.05 during trading on Monday, reaching $13.88. 70,781 shares of the company's stock traded hands, compared to its average volume of 1,462,587. The firm has a market cap of $611.14 million and a PE ratio of -3.18. Beta Bionics has a fifty-two week low of $8.89 and a fifty-two week high of $32.71. The company has a 50-day simple moving average of $25.98 and a 200-day simple moving average of $22.68.</p>
<div class="lb-trans"><p>在周一的交易中，纳斯达克：BBNX 的股票上涨了 0.05 美元，达到 13.88 美元。该公司共有 70,781 股股票交易，较其平均交易量 1,462,587 股有所减少。该公司的市值为 6.1114 亿美元，市盈率为-3.18。Beta Bionics 的 52 周低点为 8.89 美元，52 周高点为 32.71 美元。该公司的 50 日简单移动平均线为 25.98 美元，200 日简单移动平均线为 22.68 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In related news, CFO Stephen Feider sold 20,000 shares of Beta Bionics stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares of the company's stock, valued at $1,258,391.42. This trade represents a 31.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, insider Mike Mensinger sold 7,800 shares of the firm's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.61, for a total value of $230,958.00. Following the transaction, the insider directly owned 82,952 shares in the company, valued at $2,456,208.72. This trade represents a 8.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 32,490 shares of company stock worth $960,835 over the last three months.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Stephen Feider 在 1 月 2 日的交易中出售了 20,000 股 Beta Bionics 的股票。这些股票的平均售价为 29.53 美元，总交易额为 590,600.00 美元。交易完成后，首席财务官持有公司 42,614 股股票，价值 1,258,391.42 美元。这笔交易代表了他们持股比例的 31.94% 的减少。该出售在向证券交易委员会的备案中披露，相关信息可在 SEC 网站上找到。此外，内部人士 Mike Mensinger 在 1 月 2 日的交易中出售了 7,800 股公司的股票。这些股票的平均售价为 29.61 美元，总价值为 230,958.00 美元。交易完成后，该内部人士直接持有公司 82,952 股股票，价值 2,456,208.72 美元。这笔交易代表了他们持股比例的 8.59% 的减少。该出售的 SEC 备案提供了更多信息。在过去三个月中，内部人士共出售了价值 960,835 美元的 32,490 股公司股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company's stock worth $44,036,000 after buying an additional 1,509,217 shares during the last quarter. Divisadero Street Capital Management LP acquired a new stake in Beta Bionics in the 2nd quarter valued at about $13,817,000. Sands Capital Alternatives LLC raised its position in Beta Bionics by 15.0% in the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company's stock valued at $51,981,000 after purchasing an additional 466,331 shares in the last quarter. Soleus Capital Management L.P. increased its stake in Beta Bionics by 12.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company's stock valued at $55,622,000 after buying an additional 424,817 shares during the period. Finally, Pura Vida Investments LLC boosted its holdings in shares of Beta Bionics by 11,150.0% during the third quarter. Pura Vida Investments LLC now owns 281,250 shares of the company's stock worth $5,588,000 after purchasing an additional 278,750 shares during the last quarter.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。先锋集团（Vanguard Group Inc.）在第三季度将其在 Beta Bionics 的持股比例提高了 213.5%。先锋集团目前拥有 2,216,185 股公司股票，价值 44,036,000 美元，在上个季度又购买了 1,509,217 股。Divisadero Street Capital Management LP 在第二季度获得了 Beta Bionics 的新股份，价值约为 13,817,000 美元。Sands Capital Alternatives LLC 在第二季度将其在 Beta Bionics 的持股比例提高了 15.0%。Sands Capital Alternatives LLC 目前拥有 3,570,113 股公司股票，价值 51,981,000 美元，在上个季度又购买了 466,331 股。Soleus Capital Management L.P.在第二季度将其在 Beta Bionics 的持股比例提高了 12.5%。Soleus Capital Management L.P.目前拥有 3,820,158 股公司股票，价值 55,622,000 美元，在此期间又购买了 424,817 股。最后，Pura Vida Investments LLC 在第三季度将其在 Beta Bionics 的持股比例提高了 11,150.0%。Pura Vida Investments LLC 目前拥有 281,250 股公司股票，价值 5,588,000 美元，在上个季度又购买了 278,750 股。</p>
</div><h2>Beta Bionics Company Profile</h2>
<div class="lb-trans"><h2>Beta Bionics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.</p>
<div class="lb-trans"><p>Beta Bionics 是一家总部位于马萨诸塞州波士顿的临床阶段医疗设备公司，专注于通过自动胰岛素输送解决方案来彻底改变 1 型糖尿病的管理。该公司的旗舰产品 iLet Bionic Pancreas 系统旨在通过自动调整胰岛素剂量以响应连续血糖监测数据，从而简化血糖控制。通过将先进的算法控制与可穿戴输注泵相结合，iLet 旨在减少糖尿病管理的日常负担，并改善患者的临床结果。</p>
</div><p>At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.</p>
<div class="lb-trans"><p>Beta Bionics 产品的核心是其专有的仿生胰腺软件，该软件可以在仅胰岛素和双激素模式下运行。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Beta Bionics</li>
<li>Trump just signed it</li>
<li>This is the Exact Moment the AI Boom Will End</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
<li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Beta Bionics 更好</li>
<li>特朗普刚刚签署了</li>
<li>这是人工智能繁荣结束的确切时刻</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkJOWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BBNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Beta Bionics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Beta Bionics 吗？</h2>
</div><p>Before you consider Beta Bionics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Beta Bionics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Beta Bionics 并不在名单上。</p>
</div><p>While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Beta Bionics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Truist Financial 已经降低了对 Beta Bionics（NASDAQ:BBNX）股票价格的预期